Matches in SemOpenAlex for { <https://semopenalex.org/work/W176944265> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W176944265 endingPage "134" @default.
- W176944265 startingPage "127" @default.
- W176944265 abstract "The objective of our randomized, multicentre, double-blind, placebo-controlled study was to investigate the safety, tolerability, and antiretroviral and immunological effect of double and triple combination therapy regimens. A total of 105 antiretroviral therapy-naive patients were randomized to receive either zidovudine (300 mg twice per day) plus lamivudine (150 mg twice per day) plus nelfinavir placebo (three times per day) ( n=52), or zidovudine/lamivudine (dose as before) plus nelfinavir (750 mg three times per day) ( n=53) for 28 weeks. After this time, patients were allowed to switch to open-label zidovudine/lamivudine/nelfinavir. The overall log 10 reduction from baseline in plasma HIV-1 RNA was significantly greater in the zidovudine/lamivudine/nelfinavir group than the zidovudine/lamivudine group ( P=0.001; median treatment difference, –1.01 log 10 copies/ml; 95% confidence interval –1.23 to –0.79), as measured by the average area under the curve minus baseline over 28weeks. Increases from baseline in CD4 cell counts were statistically significantly greater in the zidovudine/lamivudine/nelfinavir group (101.5 cells/ml) than the zidovudine/lamivudine group (47.0 cells/ml; P=0.027) at week 28. Of note, the addition of nelfinavir from weeks 28–52 led to an increase in the proportion of subjects with plasma HIV-1 RNA <400 copies/ml from 17% (9/52 patients on zidovudine/lamivudine) to 50% (13/26 patients who switched to zidovudine/lamivudine/nelfinavir). Incidence of drug-related adverse events was similar in the two groups, except for nausea (more common in zidovudine/lamivudine group; 40 versus 17%) and diarrhoea (more common in zidovudine/lamivudine/nelfinavir group; 45 versus 14%). In conclusion, our study confirms the efficacy of triple combination therapy with two nucleoside analogues and a protease inhibitor compared with double-nucleoside therapy. Interestingly, the addition of nelfinavir to zidovudine/lamivudine, even after 6 months of double nucleoside therapy, led to a substantial virological benefit that was sustained over 24weeks in a subset of patients." @default.
- W176944265 created "2016-06-24" @default.
- W176944265 creator A5017960080 @default.
- W176944265 date "2000-02-01" @default.
- W176944265 modified "2023-10-14" @default.
- W176944265 title "Avanti 3: A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Lamivudine plus Zidovudine versus Lamivudine plus Zidovudine plus Nelfinavir in HIV-1-Infected Antiretroviral-Naive Patients" @default.
- W176944265 cites W1857344328 @default.
- W176944265 cites W1976431061 @default.
- W176944265 cites W1979721624 @default.
- W176944265 cites W2017854107 @default.
- W176944265 cites W2062388675 @default.
- W176944265 cites W2103737563 @default.
- W176944265 cites W2133158823 @default.
- W176944265 cites W2144838726 @default.
- W176944265 cites W2152464646 @default.
- W176944265 cites W2321852728 @default.
- W176944265 cites W2329393410 @default.
- W176944265 cites W2339219218 @default.
- W176944265 cites W4213297328 @default.
- W176944265 cites W4300951453 @default.
- W176944265 doi "https://doi.org/10.1177/135965350100600206" @default.
- W176944265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11491417" @default.
- W176944265 hasPublicationYear "2000" @default.
- W176944265 type Work @default.
- W176944265 sameAs 176944265 @default.
- W176944265 citedByCount "28" @default.
- W176944265 countsByYear W1769442652012 @default.
- W176944265 countsByYear W1769442652017 @default.
- W176944265 crossrefType "journal-article" @default.
- W176944265 hasAuthorship W176944265A5017960080 @default.
- W176944265 hasBestOaLocation W1769442651 @default.
- W176944265 hasConcept C126322002 @default.
- W176944265 hasConcept C142462285 @default.
- W176944265 hasConcept C142724271 @default.
- W176944265 hasConcept C159047783 @default.
- W176944265 hasConcept C168563851 @default.
- W176944265 hasConcept C197934379 @default.
- W176944265 hasConcept C204787440 @default.
- W176944265 hasConcept C2522874641 @default.
- W176944265 hasConcept C27081682 @default.
- W176944265 hasConcept C2776452011 @default.
- W176944265 hasConcept C2777210460 @default.
- W176944265 hasConcept C2777869810 @default.
- W176944265 hasConcept C2778375690 @default.
- W176944265 hasConcept C2780216070 @default.
- W176944265 hasConcept C2780593183 @default.
- W176944265 hasConcept C2780727368 @default.
- W176944265 hasConcept C2781160516 @default.
- W176944265 hasConcept C2993143319 @default.
- W176944265 hasConcept C3013748606 @default.
- W176944265 hasConcept C71924100 @default.
- W176944265 hasConcept C90924648 @default.
- W176944265 hasConcept C98274493 @default.
- W176944265 hasConceptScore W176944265C126322002 @default.
- W176944265 hasConceptScore W176944265C142462285 @default.
- W176944265 hasConceptScore W176944265C142724271 @default.
- W176944265 hasConceptScore W176944265C159047783 @default.
- W176944265 hasConceptScore W176944265C168563851 @default.
- W176944265 hasConceptScore W176944265C197934379 @default.
- W176944265 hasConceptScore W176944265C204787440 @default.
- W176944265 hasConceptScore W176944265C2522874641 @default.
- W176944265 hasConceptScore W176944265C27081682 @default.
- W176944265 hasConceptScore W176944265C2776452011 @default.
- W176944265 hasConceptScore W176944265C2777210460 @default.
- W176944265 hasConceptScore W176944265C2777869810 @default.
- W176944265 hasConceptScore W176944265C2778375690 @default.
- W176944265 hasConceptScore W176944265C2780216070 @default.
- W176944265 hasConceptScore W176944265C2780593183 @default.
- W176944265 hasConceptScore W176944265C2780727368 @default.
- W176944265 hasConceptScore W176944265C2781160516 @default.
- W176944265 hasConceptScore W176944265C2993143319 @default.
- W176944265 hasConceptScore W176944265C3013748606 @default.
- W176944265 hasConceptScore W176944265C71924100 @default.
- W176944265 hasConceptScore W176944265C90924648 @default.
- W176944265 hasConceptScore W176944265C98274493 @default.
- W176944265 hasIssue "2" @default.
- W176944265 hasLocation W1769442651 @default.
- W176944265 hasLocation W1769442652 @default.
- W176944265 hasOpenAccess W176944265 @default.
- W176944265 hasPrimaryLocation W1769442651 @default.
- W176944265 hasRelatedWork W1964016451 @default.
- W176944265 hasRelatedWork W2052363694 @default.
- W176944265 hasRelatedWork W2132421451 @default.
- W176944265 hasRelatedWork W2297526780 @default.
- W176944265 hasRelatedWork W2313444624 @default.
- W176944265 hasRelatedWork W2412482761 @default.
- W176944265 hasRelatedWork W2419372290 @default.
- W176944265 hasRelatedWork W4301216632 @default.
- W176944265 hasRelatedWork W73187075 @default.
- W176944265 hasRelatedWork W2188450143 @default.
- W176944265 hasVolume "6" @default.
- W176944265 isParatext "false" @default.
- W176944265 isRetracted "false" @default.
- W176944265 magId "176944265" @default.
- W176944265 workType "article" @default.